Secondary pharmaceutical manufacturing typically includes the final formulation, so the need to meet current Good Manufacturing Practice (cGMP) regulations and quality standards are paramount.

​

Conventional methodology uses a series of clean rooms which incurs significant construction and operational costs and handling new, highly toxic powders may be problematical.

​

​Alternatively, with careful thought and design, all areas of the plant can be contained by interfacing the processes in semi-continuous design and guaranteeing both a high level of protection and an increase in productivity.